Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus DIOVAN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus DIOVAN HCT.
DEMI-REGROTON vs DIOVAN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Valsartan: 6 hours; hydrochlorothiazide: 6–15 hours (mean 9.6 hours). Clinical context: allows once-daily dosing; half-life prolonged in renal impairment.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Valsartan: primarily biliary (83%) and renal (13%) as unchanged drug; hydrochlorothiazide: renal (≥95%) as unchanged drug.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination